Bright Minds Biosciences (DRUG) Cash from Operations (2019 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Cash from Operations data on file, last reported at 6742308.75 in Q1 2026.

• Quarterly Cash from Operations fell 498.9% year-over-year to 6742308.75 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20020782.59 (down 9572.95% YoY) and the FY2025 annual result came in at 6315634.6, down 365.66% from the prior year.
• Cash from Operations eased to 6742308.75 in Q1 2026, from 4170502.83 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 2878012.84 in Q1 2022 to a low of 19203648.9 in Q3 2022.
• A 5-year average of 2233233.59 and a median of 597467.18 in 2024 frame the typical range for Cash from Operations.
• The widest YoY moves for Cash from Operations: up 182.9% in 2025, down 4562.31% in 2025.
• Tracing DRUG's Cash from Operations over 5 years: stood at 1962334.99 in 2022, then sank by 69.23% to 603852.11 in 2023, then surged by 77.16% to 1069760.66 in 2024, then sank by 489.85% to 4170502.83 in 2025, then slumped by 61.67% to 6742308.75 in 2026.
• The last three Cash from Operations figures came in at 6742308.75 (Q1 2026), 4170502.83 (Q4 2025), and 921379.0 (Q3 2025), per Business Quant data.